Related Experiment Videos
Development of ZD1839 in colorectal cancer
1AstraZeneca Pharmaceuticals, LP, Wilmington, DE 19850, USA.
Abstract:
Colorectal cancer is one of the most frequent human malignancies. Therapeutic options are mainly limited to chemotherapy with 5-fluorouracil in various schedules or in combination with irinotecan and oxaliplatin; however, novel approaches are also in development. These new agents specifically attack molecular targets involved in tumor biology. One such target is the epidermal growth factor receptor (EGFR), which is highly expressed in many tumors and is associated with a poor prognosis. The EGFR plays a key role in cell proliferation and has been implicated in several processes that mediate cancer progression. ZD1839 is an orally active, selective EGFR tyrosine kinase inhibitor that has shown extensive preclinical activity and favorable tolerability in advanced clinical trials in a variety of tumors. In colorectal cancer cells, ZD1839 has shown both in vitro and in vivo antitumor activity as monotherapy or in combination with cytotoxic agents such as paclitaxel and irinotecan. Preclinical data have also shown that ZD1839 reverses resistance to irinotecan and enhances its efficacy by improving oral bioavailability. These studies indicate that EGFR inhibition by ZD1839 may have a valuable role in the treatment of colorectal cancer, and clinical studies in patients with colorectal cancer are ongoing.
Insights
Epidermal Growth Factor Receptor (EGFR) inhibition with ZD1839 shows promise for colorectal cancer treatment. This targeted therapy demonstrates antitumor activity and enhances chemotherapy efficacy in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer is a common malignancy with limited therapeutic options.
- Current treatments include chemotherapy (5-fluorouracil, irinotecan, oxaliplatin).
- Novel targeted therapies are under development to address tumor-specific molecular pathways.
Purpose of the Study:
- To evaluate the efficacy of ZD1839, a selective EGFR tyrosine kinase inhibitor, in colorectal cancer.
- To investigate ZD1839 as monotherapy and in combination with cytotoxic agents.
- To assess ZD1839's potential to overcome chemoresistance and improve drug bioavailability.
Main Methods:
- Preclinical evaluation of ZD1839 in colorectal cancer cells (in vitro and in vivo).
- Assessment of ZD1839's activity alone and combined with paclitaxel and irinotecan.
- Pharmacokinetic studies to evaluate oral bioavailability enhancement.
Main Results:
- ZD1839 exhibited significant antitumor activity in colorectal cancer models.
- Combination therapy with ZD1839 and cytotoxic agents demonstrated enhanced efficacy.
- ZD1839 reversed irinotecan resistance and improved its oral bioavailability.
Conclusions:
- EGFR inhibition by ZD1839 represents a potential therapeutic strategy for colorectal cancer.
- ZD1839 shows promise as both a monotherapy and an adjunct to chemotherapy.
- Ongoing clinical trials are investigating the role of ZD1839 in colorectal cancer patients.